Metabolic effects of glucagon-like peptide-1 receptor agonists The arGLP-1 s show a potent antihyperglycemic effect with decreases between 0.5% and 1.3% of HbA1c, which is greater in those with a long half-life56 with low risk of hypoglycemia, as has been shown in cardiovascular safety studies, where there were no differences in hypoglycemia rates versus placebo, except if associated with sulfonylureas or insulin.5764 The low risk of hypoglycemia has been observed even in patients with DKD.6567 who are more susceptible to this complication.16 It is also important to highlight the loss of weight and waist circumference with arGLP-1, mainly as a consequence of a reduction in body fat and not in lean mass, which is maintained during long-term follow-up.68 This weight loss is attributed to the slowing of gastric emptying which increases satiety, to the increase in resting energy consumption and its direct effects on appetite and satiety control centers in the CNS
And more importantly, will it ever go away? If youre taking a GLP-1 medication like Ozempic, Wegovy, Mounjaro, or Zepbound, youre not alone in experiencing nausea
Personalized Weight Management Timing During Lactation The postpartum timeline significantly influences medication safety and effectiveness
Prior to seeing your medical provider, we recommend checking your plans benefits to see if weight loss medicine is covered, and if so, for what particular diagnoses
A common question is whether to administer GLP-1 injections in the morning or at night
Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial
